{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:02:12Z","timestamp":1784883732656,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00380-022-02111-1","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T09:02:31Z","timestamp":1655974951000},"page":"1985-1994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantation"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-3702","authenticated-orcid":false,"given":"Hrvoje","family":"Gasparovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Jakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper J.","family":"Brugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catherine","family":"Pouleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rubi\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvinas","family":"Gaizauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline M.","family":"Van Craenenbroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Barge-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Paolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Amario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar \u00d6.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Meyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Droogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Wierzbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Holcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Planinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lovric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas J.","family":"Flammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mate","family":"Petricevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Biocina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Milicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Cikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"2111_CR1","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejhf.1236","volume":"20","author":"MG Crespo-Leiro","year":"2018","unstructured":"Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, Gustafsson F, Tsui S, Barge-Caballero E, De Jonge N, Frigerio M, Hamdan R, Hasin T, H\u00fclsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A, Ruhparwar A, Ristic AD, Straburzynska-Migaj E, McDonagh T, Seferovic P, Ruschitzka F (2018) Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20:1505\u20131535","journal-title":"Eur J Heart Fail"},{"key":"2111_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/eurheartj\/ehx036","volume":"40","author":"MR Mehra","year":"2019","unstructured":"Mehra MR (2019) The burden of hemocompatibility with left ventricular assist systems: a complex weave. Eur Heart J 40:673\u2013677","journal-title":"Eur Heart J"},{"key":"2111_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.athoracsur.2017.01.114","volume":"104","author":"H Gasparovic","year":"2017","unstructured":"Gasparovic H, Kopjar T, Saeed D, Cikes M, Svetina L, Petricevic M, Lovric D, Milicic D, Biocina B (2017) De novo aortic regurgitation after continuous-flow left ventricular assist device implantation. Ann Thorac Surg 104:704\u2013711","journal-title":"Ann Thorac Surg"},{"key":"2111_CR4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.healun.2018.07.002","volume":"37","author":"N Bouabdallaoui","year":"2018","unstructured":"Bouabdallaoui N, El-Hamamsy I, Pham M, Giraldeau G, Parent MC, Carrier M, Rouleau JL, Ducharme A (2018) Aortic regurgitation in patients with a left ventricular assist device: a contemporary review. J Heart Lung Transplant 37:1289\u20131297","journal-title":"J Heart Lung Transplant"},{"key":"2111_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cardfail.2019.08.003","volume":"25","author":"T Imamura","year":"2019","unstructured":"Imamura T, Kim G, Nitta D, Fujino T, Smith B, Kalantari S, Nguyen A, Narang N, Holzhauser L, Grinstein J, Juricek C, Rodgers D, Song T, Ota T, Jeevanandam V, Sayer G, Uriel N (2019) Aortic insufficiency and hemocompatibility-related adverse events in patients with left ventricular assist devices. J Card Fail 25:787\u2013794","journal-title":"J Card Fail"},{"key":"2111_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/icvts\/ivt263","volume":"17","author":"JR Martina","year":"2013","unstructured":"Martina JR, Schipper ME, de Jonge N, Ramjankhan F, de Weger RA, Lahpor JR, Vink A (2013) Analysis of aortic valve commissural fusion after support with continuous-flow left ventricular assist device. Interact Cardiovasc Thorac Surg 17:616\u2013624","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2111_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.healun.2015.10.022","volume":"35","author":"S Bhagra","year":"2016","unstructured":"Bhagra S, Bhagra C, \u00d6zalp F, Butt T, Ramesh BC, Parry G, Roysam C, Woods A, Robinson-Smith N, Wrightson N, MacGowan GA, Schueler S (2016) Development of de novo aortic valve incompetence in patients with the continuous-flow HeartWare ventricular assist device. J Heart Lung Transplant 35:312\u2013319","journal-title":"J Heart Lung Transplant"},{"key":"2111_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.tcm.2019.05.013","volume":"30","author":"K Sidhu","year":"2020","unstructured":"Sidhu K, Lam PH, Mehra MR (2020) Evolving trends in mechanical circulatory support: clinical development of a fully magnetically levitated durable ventricular assist device. Trends Cardiovasc Med 30:223\u2013229","journal-title":"Trends Cardiovasc Med"},{"key":"2111_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1161\/CIRCHEARTFAILURE.109.917765","volume":"3","author":"J Cowger","year":"2010","unstructured":"Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Kolias TJ (2010) The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail 3:668\u2013674","journal-title":"Circ Heart Fail"},{"key":"2111_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ejhf.1568","volume":"21","author":"M Cikes","year":"2019","unstructured":"Cikes M, Jakus N, Claggett B, Brugts JJ, Timmermans P, Pouleur AC, Rubis P, Van Craenenbroeck EM, Gaizauskas E, Grundmann S, Paolillo S, Barge-Caballero E, D\u2019Amario D, Gkouziouta A, Planinc I, Veenis JF, Jacquet LM, Houard L, Holcman K, Gigase A, Rega F, Rucinskas K, Adamopoulos S, Agostoni P, Biocina B, Gasparovic H, Lund LH, Flammer AJ, Metra M, Milicic D, Ruschitzka F, PCHF-VAD registry, (2019) Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. Eur J Heart Fail 21:1129\u20131141","journal-title":"Eur J Heart Fail"},{"key":"2111_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","volume":"16","author":"WA Zoghbi","year":"2003","unstructured":"Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ, American Society of Echocardiography (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777\u2013802","journal-title":"J Am Soc Echocardiogr"},{"key":"2111_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u2013381","journal-title":"J Biomed Inform"},{"key":"2111_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2018.12.069","volume":"280","author":"S Kasahara","year":"2019","unstructured":"Kasahara S, Sakata Y, Nochioka K, Miura M, Abe R, Sato M, Aoyanagi H, Fujihashi T, Yamanaka S, Shiroto T, Sugimura K, Takahashi J, Miyata S, Shimokawa H (2019) Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases. Int J Cardiol 280:184\u2013189","journal-title":"Int J Cardiol"},{"key":"2111_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cjca.2019.11.022","volume":"36","author":"PE Noly","year":"2020","unstructured":"Noly PE, Pagani FD, Noiseux N, Stulak JM, Khalpey Z, Carrier M, Maltais S (2020) Continuous-flow left ventricular assist devices and valvular heart disease: a comprehensive review. Can J Cardiol 36:244\u2013260","journal-title":"Can J Cardiol"},{"key":"2111_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/MAT.0000000000000443","volume":"63","author":"A Aliseda","year":"2017","unstructured":"Aliseda A, Chivukula VK, Mcgah P, Prisco AR, Beckman JA, Garcia GJ, Mokadam NA, Mahr C (2017) LVAD outflow graft angle and thrombosis risk. ASAIO J 63:14\u201323","journal-title":"ASAIO J"},{"key":"2111_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/MAT.0000000000000391","volume":"62","author":"D Saeed","year":"2016","unstructured":"Saeed D, Westenfeld R, Maxhera B, Keymel S, Sherif A, Sadat N, Petrov G, Albert A, Lichtenberg A (2016) Prevalence of De novo aortic valve insufficiency in patients after HeartWare VAD implantation with an intermittent low-speed algorithm. ASAIO J 62:565\u2013570","journal-title":"ASAIO J"},{"key":"2111_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s10047-017-1006-1","volume":"21","author":"K Iizuka","year":"2018","unstructured":"Iizuka K, Nishinaka T, Ichihara Y, Miyamoto T, Yamazaki K (2018) Outflow graft anastomosis site design could be correlated to aortic valve regurgitation under left ventricular assist device support. J Artif Organs 21:150\u2013155","journal-title":"J Artif Organs"},{"key":"2111_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCHEARTFAILURE.113.000878","volume":"7","author":"UP Jorde","year":"2014","unstructured":"Jorde UP, Uriel N, Nahumi N, Bejar D, Gonzalez-Costello J, Thomas SS, Han J, Morrison KA, Jones S, Kodali S, Hahn RT, Shames S, Yuzefpolskaya M, Colombo P, Takayama H, Naka Y (2014) Prevalence, significance, and management of aortic insufficiency in continuous flow left ventricular assist device recipients. Circ Heart Fail 7:310\u2013319","journal-title":"Circ Heart Fail"},{"key":"2111_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jcmg.2015.06.020","volume":"9","author":"J Grinstein","year":"2016","unstructured":"Grinstein J, Kruse E, Sayer G, Fedson S, Kim GH, Jorde UP, Juricek C, Ota T, Jeevanandam V, Lang RM, Uriel N (2016) Accurate quantification methods for aortic insufficiency severity in patients with LVAD: role of diastolic flow acceleration and systolic-to-diastolic peak velocity ratio of outflow cannula. JACC Cardiovasc Imaging 9:641\u2013651","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-022-02111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-022-02111-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-022-02111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T03:28:41Z","timestamp":1666150121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-022-02111-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2111"],"URL":"https:\/\/doi.org\/10.1007\/s00380-022-02111-1","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Gasparovic has nothing to disclose. Dr. Jakus reports non-financial support from Servier, personal fees from Teva Pharmaceutical Industries, personal fees from Krka, non-financial support from Abbott, personal fees from Sanofi Genzyme, outside the submitted work. Dr. Brugts reports grants and personal fees from Abbott, outside the submitted work. Dr. Pouleur reports Advisory Board\/Speaker Fee for Astra-Zeneca, MSD, Bayer, Novartis, Actelion, Pfizer. Dr. Timmermans has nothing to disclose. Dr. Rubi\u015b has nothing to disclose. Dr. Gaizauskas has nothing to disclose. Dr. Van Craenenbroeck has nothing to disclose. Dr. Barge-Caballero reports grants from ABBOT, personal fees from ABBOT, other from MEDTRONIC, outside the submitted work. Dr. Grundmann has nothing to disclose. Dr. Paolillo has nothing to disclose. Dr. D'Amario has nothing to disclose. Dr. Braun has nothing to disclose. Dr. Meyns has nothing to disclose. Dr. Droogne has nothing to disclose. Dr. Wierzbicki has nothing to disclose. Dr. Holcman has nothing to disclose. Dr. Planinc reports personal fees from Boehringer Ingelheim, personal fees from Teva Pharmaceutical Industries, personal fees and non-financial support from Novartis, personal fees and non-financial support from Pfizer, personal fees from Servier, personal fees and non-financial support from Krka, personal fees and non-financial support from Bayer, personal fees from Sandoz, personal fees from Corvia, personal fees and non-financial support from Abbott, non-financial support from Sanofi Aventis, outside the submitted work. Dr. Lovric reports personal fees and non-financial support from Astra Zeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Novartis, personal fees from Pliva, personal fees from Servier, personal fees from Sandoz, personal fees from Krka Pharma, personal fees and non-financial support from PharmaS, non-financial support from Pfizer, personal fees from Bayer, personal fees from Pharma Swiss, personal fees from Berlin Chemie, non-financial support from Sanofi Genzyme, personal fees from Novo-Nordisc, personal fees from Mylan, personal fees from CSL Behring, personal fees from Belupo, personal fees from Amgen, personal fees from Alkaloid, outside the submitted work. Dr. Flammer reports personal fees from Alnylam, grants and personal fees from AstraZeneca, personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Fresenius, personal fees from Imedos GmBH, personal fees from Medtronic, personal fees from MSD, personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Roche, personal fees from Vifor, personal fees from Zoll, grants from Berlin Heart, outside the submitted work. Dr. Petricevic has nothing to disclose. Dr. Biocina has nothing to disclose. Dr. Lund reports personal fees from Merck, grants and personal fees from Vifor-Fresenius, grants and personal fees from AstraZeneca, grants and personal fees from Relypsa, personal fees from Bayer, grants from Boston Scientific, personal fees from Pharmacosmos, personal fees from Abbott, personal fees from Medscape, personal fees from Myokardia, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, personal fees from Sanofi, personal fees from Lexicon, outside the submitted work. Dr. Milicic reports personal fees from Boehringer Ingelheim, personal fees from Bayer, personal fees from Pfizer, personal fees from Novartis, personal fees from AstraZeneca, personal fees from Novo Nordisk, personal fees from Teva, personal fees from Servier, outside the submitted work. Dr. Ruschitzka has not received personal payments by pharmaceutical companies or device manufacturers in the last three years (remuneration for the time spent in activities, such as participation in steering committee member of clinical trials, were made directly to the University of Zurich). The Department of Cardiology (University Hospital of Zurich\/University of Zurich) reports research-, educational- and\/or travel grants from Abbott, Amgen, Astra Zeneca, Bayer, B. Braun, Biosense Webster, Biosensors Europe AG, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Bracco, Cardinal Health Switzerland, Daiichi, Diatools AG, Edwards Lifesciences, Guidant Europe NV (BS), Hamilton Health Sciences, Kaneka Corporation, Labormedizinisches Zentrum, Medtronic, MSD, Mundipharma Medical Company, Novartis, Novo Nordisk, Orion, Pfizer, Quintiles Switzerland Sarl, Sanofi, Sarstedt AG, Servier, SIS Medical, SSS International Clinical Research, Terumo Deutschland, V- Wave, Vascular Medical, Vifor, Wissens Plus, ZOLL. The research and educational grants do not impact on Prof. Ruschitzka`s personal remuneration. Dr. Cikes reports grants and personal fees from Novartis, grants and non-financial support from Abbott, personal fees and non-financial support from GE Healthcare, non-financial support from Corvia, personal fees and non-financial support from Pfizer, personal fees from Bayer, personal fees from Boehringer-Ingelheim, personal fees from AstraZeneca, personal fees from Sanofi, personal fees and non-financial support from Teva Pharmaceutical Industries, personal fees from Orion Pharma, personal fees from Medtronic, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}